Finance entity
Every one of those 2 sits in a single category, earnings. Celanese is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 175-day span. Their average consequence score of 5.5 runs below the beat's 6.3 for that window.
Last mentioned: 4d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, earnings. Celanese is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 175-day span. Their average consequence score of 5.5 runs below the beat's 6.3 for that window. Each story carries 2.5 original sources on average, compared with 2.7 for the broader beat in this window. Halozyme Therapeutics appears in 2 tracked Finance stories published from February 19, 2026 through August 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 4165 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Halozyme Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
A wave of earnings reports from Halozyme Therapeutics, Celanese, and OneSpaWorld has revealed significant bottom-line misses, highlighting growing cost pressures and demand volatility. While Halozyme managed a revenue beat, its massive EPS shortfall points to substantial operational or one-time headwinds that are rattling investor confidence.
Halozyme Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
